Ullem Scott B. 4

What Happened

• Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences (EW), exercised 13,000 stock options on March 11, 2026 at an exercise price of $59.26 per share (total cost ~$770,337). On the same day he sold 13,000 shares in open-market trades for total gross proceeds of ~$1,103,896 (two weighted-average sale prices reported: $84.46 and $85.21).
• Net of the exercise cost, proceeds exceeded the exercise amount by roughly $333,559. The filing also shows a derivative disposition entry for 13,000 shares at $0.00, which reflects the mechanics of the exercise/sale as reported on Form 4.

Key Details

• Transaction date: March 11, 2026.
• Exercise: 13,000 shares @ $59.26 = $770,337 (code M — option exercise/conversion).
• Sales: 5,099 shares @ $84.46 (weighted avg; price range $83.865–$84.860) = $430,668; 7,901 shares @ $85.21 (weighted avg; range $84.865–$85.790) = $673,228. Total sold = 13,000 shares for ~$1,103,896.
• Additional derivative line: 13,000 shares listed as disposed at $0.00 (reported as part of exercise mechanics).
• Shares owned after transaction: not disclosed in this Form 4.
• Footnotes: Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted July 29, 2025. Weighted-average sale prices reflect multiple trades; detailed trade-level prices available upon request to SEC staff, the issuer, or a security holder.
• Timeliness: Filing date and Period of Report are both March 11, 2026 — appears timely.

Context

• This is effectively a simultaneous exercise and sale (cashless-style outcome): Ullem paid to exercise options and sold the resulting shares the same day. Such transactions are common for executives monetizing vested options and do not, by themselves, indicate a change in company outlook.
• The 10b5-1 plan note means the sales were executed under a pre-set trading plan, which is intended to avoid claims of trading on inside information.